Lung Cancer

Combination therapies with neoadjuvant ICIs and chemotherapy followed by an adjuvant ICI are here to stay in resectable non–small cell lung cancer.

Sally Lau, MD, discusses the addition of tarlatamab to a PD-L1 inhibitor as first-line maintenance therapy for extensive-stage small cell lung cancer.

Andrea Wolf, MD, MPH, discusses challenges experienced when conducting randomized trials to assess the role of surgery in mesothelioma management.

A next generation sequencing–based companion diagnostic has received marketing approval in China for sunvozertinib in EGFR exon 20–positive NSCLC.

Jacob Sands, MD, discusses updated efficacy findings with tarlatamab treatment in previously treated patients with small cell lung cancer.

Eric Kumar Singhi, MD, discusses the current therapeutic landscape and unmet needs in small cell and non–small cell lung cancer.

John V. Heymach, MD, PhD, and Marina Chiara Garassino, MD, detail the 11-0 ODAC vote that new trial designs for perioperative regimens in resectable NSCLC should include within-trial assessment of each treatment phase's contribution.

Marina Chiara Garassino, MD, discusses the predictive utility of a TROP2 computational pathway biomarker for outcomes with Dato-DXd in pretreated NSCLC.

Nicolas Girard, MD, discusses the safety of nivolumab plus relatlimab and chemotherapy for untreated stage IV or recurrent non–small cell lung cancer.

Martin Dietrich, MD, PhD, discusses updated efficacy findings from the 18-month follow-up of the phase 2 VISION trial.

Isabel Preeshagul, DO, MBS, discusses ongoing efforts to expand treatment options for patients with extensive- or limited-stage small cell lung cancer.

Isabel Preeshagul, DO, MBS, and colleagues share updates from across the lung cancer space as discussed in a recent State of the Science Summit.

Atezolizumab administered concurrently with chemoradiation failed to improve OS and PFS outcomes compared with standard chemoradiation alone in LS-SCLC.

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.

Here is your snapshot of all treatment options that the FDA approved in September 2024.

Benjamin Besse, MD, PhD, discusses mechanisms of resistance to amivantamab plus lazertinib vs osimertinib in patients with EGFR-mutant, advanced NSCLC.

Isabel Preeshagul, DO, MBS, discusses considerations for treatment selection in the first and second line for patients with EGFR-mutated NSCLC.

The FDA has approved nivolumab with platinum chemotherapy as neoadjuvant treatment, followed by single-agent nivolumab after surgery, in resectable NSCLC.

Nicolas Girard, MD, discusses PROs from the LUMINOSITY trial of Teliso-V in patients with c-Met protein–overexpressing, EGFR wild-type, nonsquamous NSCLC.

Treatment with Deltacel was safe and showed antitumor activity at 10 months in a patient with stage IV metastatic non–small cell lung cancer.

The FDA’s ODAC votes against the risk:benefit profile of frontline PD-1 inhibitors in select tumor types, osimertinib gains approval for select NSCLC, and more this week from OncLive.

Shirish M. Gadgeel, MD, on long-term follow-up data from MARIPOSA for amivantamab plus lazertinib in first-line EGFR-mutated non–small cell lung cancer.

Jacob Sands, MD, discusses consolidation therapy durvalumab as a new standard of care in limited-stage small cell lung cancer.

Dr. Xiuning Le highlights real-world data on therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations, emphasizing the need for improved treatments, at ESMO Congress 2024.

The FDA approved osimertinib for EGFR-mutated, locally advanced, unresectable, non–small cell lung cancer after chemoradiation.